← Back to Screener
MaxCyte, Inc. Common Stock (MXCT)
Price$1.22
Value ScoreC
Growth ScoreD
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-41.70%
Price vs S&P 500 (4W)32.53%
VGM Score42.31
Market Capitalization$129.08M
All Metrics
Book Value / Share (Quarterly)$1.57
P/TBV (Annual)0.97x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-9.30%
Cash Flow / Share (Quarterly)$-0.28
Price vs S&P 500 (YTD)-32.87%
Gross Margin (TTM)80.51%
Net Profit Margin (TTM)-121.16%
EPS (TTM)$-0.37
10-Day Avg Trading Volume1.17M
EPS Excl Extra (TTM)$-0.37
Revenue Growth (5Y)4.76%
EPS (Annual)$-0.42
ROI (Annual)-26.02%
Gross Margin (Annual)81.16%
Net Profit Margin (5Y Avg)-88.57%
Cash / Share (Quarterly)$1.00
Revenue Growth QoQ (YoY)-7.11%
ROA (Last FY)-22.04%
Revenue Growth TTM (YoY)-14.30%
EBITD / Share (TTM)$-0.39
ROE (5Y Avg)-15.76%
Operating Margin (TTM)-141.81%
Cash Flow / Share (Annual)$-0.34
P/B Ratio0.77x
P/B Ratio (Quarterly)0.45x
Net Income / Employee (Annual)$-490,400
EV / Revenue (TTM)3.55x
Net Interest Coverage (TTM)-20.44x
ROA (TTM)-18.85%
EPS Incl Extra (Annual)$-0.42
Current Ratio (Annual)8.30x
Quick Ratio (Quarterly)10.88x
3-Month Avg Trading Volume1.13M
52-Week Price Return-47.62%
Revenue / Employee (TTM)$354,800
Tangible BV / Share (Quarterly)$1.56
P/S Ratio (Annual)3.91x
Asset Turnover (Annual)0.16x
52-Week High$2.40
Operating Margin (5Y Avg)-104.43%
EPS Excl Extra (Annual)$-0.42
CapEx CAGR (5Y)-3.10%
Tangible BV CAGR (5Y)66.92%
26-Week Price Return-25.77%
Quick Ratio (Annual)7.47x
13-Week Price Return52.59%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)12.04x
Enterprise Value$114.52M
Revenue / Share Growth (5Y)-3.81%
Asset Turnover (TTM)0.16x
Book Value / Share Growth (5Y)45.14%
Revenue / Employee (Annual)$362,900
Inventory Turnover (Annual)0.76x
Pretax Margin (Annual)-135.14%
Cash / Share (Annual)$0.96
3-Month Return Std Dev78.22%
Gross Margin (5Y Avg)85.81%
Net Income / Employee (TTM)$-429,900
ROE (Last FY)-26.02%
EPS Basic Excl Extra (Annual)$-0.42
Receivables Turnover (TTM)6.61x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.37
Receivables Turnover (Annual)8.07x
ROI (TTM)-22.03%
P/S Ratio (TTM)4.00x
Pretax Margin (5Y Avg)-88.57%
Revenue / Share (Annual)$0.31
Tangible BV / Share (Annual)$1.60
Price vs S&P 500 (52W)-75.83%
Year-to-Date Return-21.94%
5-Day Price Return16.35%
EPS Normalized (Annual)$-0.42
ROA (5Y Avg)-13.65%
Net Profit Margin (Annual)-135.14%
Month-to-Date Return37.50%
Cash Flow / Share (TTM)$-0.33
EBITD / Share (Annual)$-0.45
Operating Margin (Annual)-157.14%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-15.76%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.37
P/TBV (Quarterly)0.45x
P/B Ratio (Annual)0.96x
Inventory Turnover (TTM)0.79x
Pretax Margin (TTM)-121.16%
Book Value / Share (Annual)$1.61
Price vs S&P 500 (13W)42.84%
Beta1.69x
Revenue / Share (TTM)$0.30
ROE (TTM)-22.03%
52-Week Low$0.64
vGradeC
gGradeD
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.04est. -0.08
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.15
4.15
4.15
4.15
Industry Peers — R&D — Physical Sciences(15)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MXCTMaxCyte, Inc. Common Stock | C | D | C | $1.22 |
| IQVIQVIA Holdings Inc. | C | B | B | $186.82 |
| INCYIncyte Genomics Inc | C | A | B | $95.59 |
| MEDPMedpace Holdings, Inc. Common Stock | D | A | B | $451.47 |
| ICLRIcon Plc | C | C | B | $138.03 |
| CRLCharles River Laboratories International, Inc. | D | D | B | $182.07 |
| ABSIAbsci Corporation Common Stock | F | F | A | $6.52 |
| NRCNRC Health Common Stock | D | D | B | $20.25 |
| OABIOmniAb, Inc. Common Stock | D | C | A | $2.61 |
| ONMDOneMedNet Corp Class A Common Stock | D | C | C | $0.78 |
| NOTVInotiv, Inc. Common Stock | B | B | D | $0.31 |
About
MaxCyte Inc is a commercial cell engineering company that develops and commercializes technologies for the discovery and development of next-generation cell therapeutics. The company's proprietary Flow Electroporation platform enables the efficient engineering of diverse cell types for therapeutic and research applications. MaxCyte generates revenue from the sale and licensing of its instruments and related single-use disposable processing assemblies.